Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression

Molecular Pharmacology

Volumn 78, Issue 2, 2010, Pages 310-318

  Xie, Yingqiu ^a   Burcu, Mehmet ^a   Linn, Douglas E ^a   Qiu, Yun ^a,b   Baer, Maria R ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CYCLOHEXIMIDE; DEOXYGLUCOSE; DOXORUBICIN; GLYCOPROTEIN P; PROTEASOME; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1;

ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ASSAY; ENZYME DEGRADATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; PROTECTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; SENSITIZATION;

CELL MEMBRANE; CYCLOHEXIMIDE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GLYCOSYLATION; HL-60 CELLS; HUMANS; HYDROLYSIS; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-PIM-1; UBIQUITINATION;

EID: 77954888748     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.061713     Document Type: Article

References (42)

1. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, and Koskinen PJ (2004) Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571:43-49.
2. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, and Telerman A (1989) The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 86:8857-8861.
3. 2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 38:430-443.
4. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, et al. (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224-1232.
5. Bullock AN, Debreczeni J, Amos AL, Knapp S, and Turk BE (2005) Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280:41675-41682.
6. Chambers TC, Pohl J, Glass DB, and Kuo JF (1994) Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J 299:309-315. (Pubitemid 24106324)
7. Chen CN, Lin JJ, Chen JJ, Lee PH, Yang CY, Kuo ML, Chang KJ, and Hsieh FJ (2005) Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 23:7286-7295.
8. Chen LS, Redkar S, Bearss D, Wierda WG, and Gandhi V (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114:4150-4157.
9. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, Nawijn MC, Capece D, Cohan VL, and Rothman P (2002) Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 99:2175-2180.
10. Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, Hamatake R, Hong Z, and Wu JZ (2007) Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 17:1679-1683.
11. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
12. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, and Gottesman MM (1996) Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271:1708-1716. (Pubitemid 26028661)
13. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, and Higgins CF (1996) Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 271:13668-13674.
14. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, and Ambudkar SV (2000) Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 173:203-214.
15. Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, and Dalton WS (1999) Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 59:1021-1028.
16. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, and Lilly MB (2007) Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6:163-172.
17. Kerr KM, Sauna ZE, and Ambudkar SV (2001) Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 276:8657-8664.
18. Kim HR, Oh BC, Choi JK, and Bae SC (2008) Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 105:1048-1058.
19. Kim KT, Levis M, and Small D (2006) Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol 134:500-509. (Pubitemid 44141716)
20. Kim O, Jiang T, Xie Y, Guo Z, Chen H, and Qiu Y (2004) Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23:1838-1844.
21. Liscovitch M and Ravid D (2007) A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245:350-352.
22. Loo TW and Clarke DM (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272:709-712.
23. Loo TW and Clarke DM (1998a) Quality control by proteases in the endoplasmic reticulum. Removal of a protease-sensitive site enhances expression of human P-glycoprotein. J Biol Chem 273:32373-32376.
24. Loo TW and Clarke DM (1998b) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 273:14671-14674.
25. Loo TW and Clarke DM (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 13:1724-1732.
26. Mahadevan D and Shirahatti N (2005) Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 5:445-455.
27. Minderman H, O'Loughlin KL, Pendyala L, and Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826-1834.
28. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, and Kuchino Y (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274:18659-18666.
29. Morishita D, Katayama R, Sekimizu K, Tsuruo T, and Fujita N (2008) Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 68:5076-5085.
30. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, and Jain A (2009) Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8:2882-2893.
31. Ogretmen B and Safa AR (2000) Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 39:194-204.
32. Palaty CK, Clark-Lewis I, Leung D, and Pelech SL (1997) Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 75:153-162.
33. Pétriz J, Gottesman MM, and Aran JM (2004) An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv 1:43-56.
34. Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, and Schwaller J (2007) Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 67:6916-6924.
35. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, and Baer MR (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320-2326.
36. Saris CJ, Domen J, and Berns A (1991) The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10:655-664. (Pubitemid 21905520)
37. van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, et al. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106:2646-2654.
38. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H, and Qiu Y (2006) The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25:70-78.
39. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, et al. (2008) The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283:3349-3356.
40. Zhang Y, Wang Z, Li X, and Magnuson NS (2008) Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27:4809-4819.
41. Zhang Y, Wang Z, and Magnuson NS (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5:909-922.
42. Zhang Z, Wu JY, Hait WN, and Yang JM (2004) Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66:395-403.